A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

Overview of attention for article published in Journal of Hematology & Oncology, June 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
Good Attention Score compared to outputs of the same age and source (65th percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,117 followers.

Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell #lymphoma. #DLBCL https://t.co/9YODLWCemP

New article: A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. https://t.co/rNj88e6mDk #DLBCL #lymsm #hematology https://t.co/eV6plc

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.